NCT06082336View on ClinicalTrials.gov

Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C

NARecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

September 30, 2024

Conditions
Combined Point of Care Diagnostic of HIV, HBV and HCV
Interventions
DIAGNOSTIC_TEST

MagIA IBC test in capillary blood

After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.

DIAGNOSTIC_TEST

MagIA IBC test in other matrices

Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.

Trial Locations (1)

13003

RECRUITING

Hopital Européen de Marseille, Marseille

Sponsors

Lead Sponsor

MagIA Diagnostics
All Listed Sponsors
lead

MagIA Diagnostics

INDUSTRY

NCT06082336 - Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C | Biotech Hunter | Biotech Hunter